NASDAQ:VSAR - Versartis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.80 +0.05 (+2.86 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$1.75
Today's Range$1.70 - $1.85
52-Week Range$1.35 - $22.10
Volume204,100 shs
Average Volume543,944 shs
Market Capitalization$62.51 million
P/E Ratio-0.75
Dividend YieldN/A
Beta1.89
Versartis logoVersartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.

Receive VSAR News and Ratings via Email

Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VSAR
CUSIPN/A
Phone650-963-8580

Debt

Debt-to-Equity Ratio0.11
Current Ratio16.99
Quick Ratio16.99

Price-To-Earnings

Trailing P/E Ratio-0.75
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales1,630.80
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book0.78

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-84,970,000.00
Net MarginsN/A
Return on Equity-54.03%
Return on Assets-37.80%

Miscellaneous

Employees28
Outstanding Shares36,240,000
Market Cap$62.51 million

Versartis (NASDAQ:VSAR) Frequently Asked Questions

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis Inc (NASDAQ:VSAR) posted its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.96) by $0.69. View Versartis' Earnings History.

When is Versartis' next earnings date?

Versartis is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Versartis.

What price target have analysts set for VSAR?

9 equities research analysts have issued 1-year target prices for Versartis' shares. Their predictions range from $3.00 to $14.00. On average, they expect Versartis' stock price to reach $5.1250 in the next year. This suggests a possible upside of 184.7% from the stock's current price. View Analyst Price Targets for Versartis.

What is the consensus analysts' recommendation for Versartis?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Versartis in the last year. There are currently 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Versartis.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:
  • Mr. Jay P. Shepard, Pres, CEO & Director (Age 60)
  • Ms. Tracy M. Woody, Chief Commercial Officer (Age 48)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 53)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Kevin Haas, VP of Fin. (Age 53)

Has Versartis been receiving favorable news coverage?

Press coverage about VSAR stock has been trending positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Versartis earned a daily sentiment score of 0.28 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.74 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Versartis.

Who are Versartis' major shareholders?

Versartis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (6.70%), BlackRock Inc. (3.14%), Millennium Management LLC (2.23%), Nexthera Capital LP (1.38%), Renaissance Technologies LLC (0.81%) and GSA Capital Partners LLP (0.79%). Company insiders that own Versartis stock include Colin Hislop, Edmon R Jennings, Jay S Stout, Jay Shepard, John Varian, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Perceptive Advisors Llc, Shahzad Malik, Shane Ward, Srinivas Akkaraju and Tracy M Woody. View Institutional Ownership Trends for Versartis.

Which institutional investors are selling Versartis stock?

VSAR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have sold Versartis company stock in the last year include Colin Hislop, Jay S Stout, Jay Shepard, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Shane Ward and Tracy M Woody. View Insider Buying and Selling for Versartis.

Which institutional investors are buying Versartis stock?

VSAR stock was purchased by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Nexthera Capital LP, Millennium Management LLC, Sio Capital Management LLC, Renaissance Technologies LLC, Paloma Partners Management Co, GSA Capital Partners LLP and Spark Investment Management LLC. Company insiders that have bought Versartis stock in the last two years include Perceptive Advisors Llc and Srinivas Akkaraju. View Insider Buying and Selling for Versartis.

How do I buy shares of Versartis?

Shares of VSAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of VSAR stock can currently be purchased for approximately $1.80.

How big of a company is Versartis?

Versartis has a market capitalization of $62.51 million and generates $40,000.00 in revenue each year. The biopharmaceutical company earns $-84,970,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Versartis employs 28 workers across the globe.

How can I contact Versartis?

Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected]


MarketBeat Community Rating for Versartis (NASDAQ VSAR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  446
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe VSAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.